021-51111890
购物车（）
sales@molnova.cn
VU 0134992
CAS No. 755002-90-5
VU 0134992 ( —— )
产品货号. M21660 CAS No. 755002-90-5
VU0134992 是一种 Kir4.1 阻断剂，IC50 值为 0.97 μM。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ￥1292 | 有现货 |
|
| 10MG | ￥1929 | 有现货 |
|
| 25MG | ￥3097 | 有现货 |
|
| 50MG | ￥4334 | 有现货 |
|
| 100MG | ￥5328 | 有现货 |
|
| 200MG | ￥7344 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
| 1 mL x 10 mM in DMSO | ￥1435 | 有现货 |
|
生物学信息
-
产品名称VU 0134992
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述VU0134992 是一种 Kir4.1 阻断剂，IC50 值为 0.97 μM。
-
产品描述VU0134992 is an Kir4.1 blocker with an IC50 value of 0.97 μM.
-
体外实验VU0134992 is greater than 30-fold selective for Kir4.1 over Kir1.1, Kir2.1, and Kir2.2, is weakly active toward Kir2.3, Kir6.2/SUR1, and Kir7.1, and is equally active toward Kir3.1/3.2, Kir3.1/3.4, and Kir4.2.The selectivity of VU0134992 for Kir4.1 versus nine other members of the Kir channel family was evaluated at concentrations ranging from 0.3 nM to 30 μM in 11-point CRC experiments, using established Tl+ flux assays.VU0134992 inhibits Kir3.1/Kir3.2 (92% inhibition at 30 μM, IC50=2.5 μM), Kir3.1/Kir3.4 (92% inhibition at 30 μM, IC50=3.1 μM), and Kir4.2 (100% inhibition at 30 μM, IC50=8.1 μM) with approximately the same efficacy and potency that VU0134992 inhibits Kir4.1 (100% at 30 μM, IC50=5.2 μM).
-
体内实验VU0134992 (50-100 mg/kg; oral gavage) statistically significantly increased urinary Na+ as well as K+ excretion. Animal Model:Male Sprague-Dawley rats (250-300 g)Dosage:50 and 100 mg/kg Administration:Oral gavage Result:Statistically significantly increased urinary Na+ as well as K+ excretion
-
同义词——
-
通路Cell Cycle/DNA Damage
-
靶点Potassium Channel
-
受体Kir4.1
-
研究领域——
-
适应症——
化学信息
-
CAS Number755002-90-5
-
分子量411.38
-
分子式C20H31BrN2O2
-
纯度>98% (HPLC)
-
溶解度——
-
SMILESCC(C)c1ccc(OCC(=O)NC2CC(C)(C)NC(C)(C)C2)c(Br)c1
-
化学全称2-(2-Bromo-4-isopropylphenoxy)-N-(2266-tetramethylpiperidin-4-yl)acetamide
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1.Kharade SV et al. Discovery Characterization and Effects on Renal Fluid and Electrolyte Excretion of the Kir4.1 Potassium Channel Pore Blocker VU0134992. Mol Pharmacol. 2018 Aug;94(2):926-937.
